Omideon is a biotechnology company focused on the development of novel treatments for cancer by targeting the tumour glycome. Omideon harnesses a carbohydrate-binding module (CBM) platform technology for the generation of new cancer therapeutics. Omideon's lead candidate OMI-DG1 is a first-in-class multivalent CBM in development for ovarian and colorectal cancer.
Company Details
- Employees
- 2
- Founded
- 2020
- Address
- Kinburn Castle, Doubledykes Road, St. Andrews,ky16 9dr,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.omideon.com
- HQ
- St. Andrews
Omideon Limited Questions
Omideon Limited's website is http://www.omideon.com
Omideon Limited's LinkedIn profile is https://uk.linkedin.com/company/omideon-limited
Omideon Limited has
2 employees.
View email and phone details for 2
employees at Omideon Limited.
Omideon Limited's industry is
Biotechnology Research
Omideon Limited's top competitors are
Lassogen, Inc.,
Pinetree Therapeutics Inc,
Duo Oncology,
Singula Bio Ltd.,
Incyclix Bio,
Aoa Dx,
Biovaxys Technology Corp.,
Upyther,
Accession Therapeutics Limited,
Madera Therapeutics.
Omideon Limited's categories are Biotechnology Research
Omideon Limited's founding year is 2020
